HHS announced ~$25M for psychedelics research, focusing on ibogaine via ARPA-H. Mark Cuban's Cost Plus Drugs and Beond will ...
Rezera, a biotech developing drugs for cardio and inflammatory diseases, has delayed its IPO scheduled for Friday, a company ...
FDA says its commissioner’s voucher program is still running after Reuters reports it was shelved; 22 drugs have vouchers, 12 ...
Neurosterix raises $105M Series B for M4 PAM schizophrenia drug NTX-253, adding Karuna’s Andrew Miller as executive chair.
EnGene’s latest data on its bladder cancer therapy looked better than an earlier cut in May, vut it still remains to be seen whether enGene can meaningfully challenge competitors like J&J.
FDA approves Merck KGaA’s Pimjetmi, licensed from Abbisko, for rare joint tumor TGCT, joining Ono’s Romvimza and Daiichi’s Turalio.
Hims & Hers partners with Eli Lilly and Novo on branded GLP-1s, but faces margin pressure, subscriber loss, and competition ...
CVS Health is splitting into two publicly traded companies as the healthcare giant fights rising costs, retail competition, regulatory scrutiny and other pressures. The first ...
Flagship merges Valo Health & Montai; J&J files Caplyta for bipolar mania; BrightGene's BGM0504 beats Ozempic; AstraZeneca ...
White House pushes for Heidi Overton’s FDA confirmation in the lame-duck window, with Cassidy and Murkowski as key votes.
Mirum’s hepatitis D drug brelovitug hits its Phase 3 goal in AZURE-4, setting up a 2027 filing against Gilead’s Hepcludex and ...
Oyster Therapeutics raises $60M Series A-2, with Lilly joining, for self-assembling oral degraders that target toxic tau in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results